(Q33367224)

English

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nicolas Tsavaris

1

1 reference

Europe PubMed Central

26 July 2017

Christos Kosmas

2

1 reference

Europe PubMed Central

26 July 2017

Helias Skopelitis

3

1 reference

Europe PubMed Central

26 July 2017

Panagiotis Gouveris

4

1 reference

Europe PubMed Central

26 July 2017

Petros Kopterides

5

1 reference

Europe PubMed Central

26 July 2017

Dioynissis Loukeris

6

1 reference

Europe PubMed Central

26 July 2017

Frantzeska Sigala

7

1 reference

Europe PubMed Central

26 July 2017

Alexandra Zorbala-Sypsa

8

1 reference

Europe PubMed Central

26 July 2017

Evangelos Felekouras

9

1 reference

Europe PubMed Central

26 July 2017

Efstathios Papalambros

10

1 reference

Europe PubMed Central

26 July 2017

publication date

1 August 2005

1 reference

Europe PubMed Central

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

26 July 2017

23

1 reference

Europe PubMed Central

26 July 2017

369-375

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-005-1446-y

0 references

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1446-Y

21 January 2018

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1446-Y

21 January 2018

Cancer statistics, 1998.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A systematic overview of chemotherapy effects in pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors after surgical resection for pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends in pancreatic cancer mortality in Europe, 1955–1989

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic cancer: the greatest oncological challenge

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New drugs for patients with pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic cancer: the evolving role of systemic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-005-1446-Y

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33367224&oldid=1628954103"